戻る Agenda
[V5-S3] Approaches to Enhance Appropriate Communication on Pharmaceutical Product Information
Session Chair(s)
Mamoru Narukawa, PHD, RPH
Professor, Kitasato University, Japan
Yuko Kojima, RPH
Sr. Executive Director, Eli Lilly Japan K.K., Japan
It is highly important that pharmaceutical product information is appropriately provided by regulatory authorities and pharmaceutical companies, and utilized in the medical field. In the Japan annual meeting in 2016, we discussed issues arising from provision of pharmaceutical product information materials provided to healthcare professionals or patients, and handling of these issues. We have found that pharmaceutical product information is not necessarily fully utilized by the medical professionals: duplicate information is provided using various materials from the regulatory authorities and companies, necessary information for medical professionals is not provided, and the real intentions of the authors are not fully conveyed. In 2017, we will discuss approaches and future perspectives to enhance appropriate communication on pharmaceutical product information to medical professionals based on the previous discussion by summarizing the objectives and utilization methods of a wide range of information materials provided by the regulatory authorities and companies.
Speaker(s)
Tomoko Tanita
Risk Communication Promotion Division, Office of Safety I, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Susumu Wakabayashi
Department of Pharmacy, Kyorin University Hospital, Japan
Shinya Takemoto, MSC
Group Manager, Safety Information Strategy Group, Risk Communication Department, Chugai Pharmaceutical Co., Ltd., Japan
Junichi Nishino, MSC, RPH
Head, Regulatory Affairs Department, Otsuka Pharmaceutical Co., Ltd., Japan
Toyotaka Iguchi, MD, PHD
Director, Office of Safety II, Pharmaceuticals and Medical Devices Agency (PMDA), Japan